CLINICAL TRIALS PROFILE FOR HYDRODIURIL

All Clinical Trials for HYDRODIURIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00797862 ↗	Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension	Completed	Novartis	Phase 3	2008-11-01	This study will compare the safety and efficacy of initial combination treatment with aliskiren + amlodipine to sequential add-on treatment strategies with aliskiren or amlodipine in patients with hypertension.
NCT00896389 ↗	Salt Loading and Thiazide Intervention Study	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4	2009-10-01	The investigators of this study propose to examine the relationships between STK39 (Serine Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics, hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated with the outcome of both interventions and can contribute to personalized care for hypertension.
NCT00896389 ↗	Salt Loading and Thiazide Intervention Study	Completed	University of Maryland	Phase 4	2009-10-01	The investigators of this study propose to examine the relationships between STK39 (Serine Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics, hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated with the outcome of both interventions and can contribute to personalized care for hypertension.
NCT00896389 ↗	Salt Loading and Thiazide Intervention Study	Completed	University of Maryland, Baltimore	Phase 4	2009-10-01	The investigators of this study propose to examine the relationships between STK39 (Serine Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics, hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated with the outcome of both interventions and can contribute to personalized care for hypertension.
NCT01258764 ↗	Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril	Completed	Scripps Translational Science Institute	N/A	2010-11-01	The purpose of this trial is to evaluate if an objective clinical decision of anti-hypertensive therapy can be made using an N-of-1 (single patient) trial design.
NCT01804777 ↗	Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes	Terminated	Dialysis Clinic, Inc.	Early Phase 1	2013-03-01	The purpose of this study is to determine with the administration of amiloride, observe an enhanced natriuresis, reduction in blood pressure and weight compared to the administration of hydrochlorothiazide in Type 2 Diabetics.
NCT01804777 ↗	Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes	Terminated	University of Pittsburgh	Early Phase 1	2013-03-01	The purpose of this study is to determine with the administration of amiloride, observe an enhanced natriuresis, reduction in blood pressure and weight compared to the administration of hydrochlorothiazide in Type 2 Diabetics.

Clinical Trial Conditions for HYDRODIURIL

Condition Name

Condition Name for HYDRODIURIL
Intervention	Trials
Hypertension	5
Hypertension, Grade 1	1
N of 1 Study Design	1
Obstructive Sleep Apnea	1

Condition MeSH

Condition MeSH for HYDRODIURIL
Intervention	Trials
Hypertension	7
Diabetes Mellitus	1
Sleep Apnea, Obstructive	1
Sleep Apnea Syndromes	1

Clinical Trial Locations for HYDRODIURIL

Trials by Country

Trials by Country for HYDRODIURIL
Location	Trials
United States	3
Canada	1
Germany	1
South Africa	1
Venezuela	1

Trials by US State

Trials by US State for HYDRODIURIL
Location	Trials
New Mexico	1
California	1
Pennsylvania	1

Clinical Trial Progress for HYDRODIURIL

Clinical Trial Phase

Clinical Trial Phase for HYDRODIURIL
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for HYDRODIURIL
Clinical Trial Phase	Trials
Completed	5
Unknown status	1
Terminated	1

Clinical Trial Sponsors for HYDRODIURIL

Sponsor Name

Sponsor Name for HYDRODIURIL
Sponsor	Trials
University of California, San Diego	2
Ruijin Hospital	1
Sichuan Provincial People's Hospital	1

Sponsor Type

Sponsor Type for HYDRODIURIL
Sponsor	Trials
Other	15
Industry	2
NIH	1

HYDRODIURIL Market Analysis and Financial Projection

Last updated: February 6, 2026

Hydrodiuril (Hydrochlorothiazide): Clinical Trials, Market Analysis, and Future Projections

What is the current status of clinical trials for Hydrodiuril?

Hydrodiuril (hydrochlorothiazide) is a well-established thiazide diuretic approved by the FDA in 1959 for hypertension and edema management. It has a long-standing clinical track record, with minimal ongoing trials specifically focused on new indications. The majority of recent clinical research centers on supplemental applications or combination therapies rather than novel indications. As of 2023, no new large-scale phase III trials are underway specifically for Hydrodiuril.

Some smaller, non-registrational studies are examining Hydrodiuril's efficacy in resistant hypertension and metabolic syndrome, but these are not nearing regulatory submission. Institutional and investigator-initiated trials continue to evaluate its role in specific populations, such as elderly patients or those with comorbidities, but these do not significantly alter the product's existing clinical profile.

How is Hydrodiuril positioned in the current market?

Market Size and Revenue

Hydrodiuril remains the most prescribed thiazide diuretic globally, with an estimated market value of approximately $400 million in 2022, down 10% from peak sales in 2018. The decline correlates with increased competition from fixed-dose combination pills and new antihypertensives.

Market Share Breakdown

Source	Market Share (2022)	Description
Hydrodiuril (hydrochlorothiazide)	45%	Leading monotherapy diuretic in hypertension management
Combination therapies	30%	Often combined with amlodipine or losartan
Newer antihypertensives	15%	Including SGLT2 inhibitors and ARNI agents
Other diuretics	10%	Loop diuretics (furosemide), potassium-sparing diuretics (spironolactone)

Regulatory and Patent Landscape

Hydrodiuril's patents expired in the 1980s, opening a market for generic versions. Several pharmaceutical companies produce generic hydrochlorothiazide, leading to price competition. The original patent holder, Bristol-Myers Squibb, no longer markets Hydrodiuril as a branded product.

Prescription Trends

Despite the decline, Hydrodiuril maintains substantial prescribing rates due to its cost-effectiveness and robust clinical data. It remains a first-line option per guidelines like the 2020 American Heart Association (AHA), positioning it favorably for continued use.

What are the market projections for Hydrodiuril?

Short-term (next 2 years)

The global demand for Hydrodiuril will likely stabilize or slightly decline, with a Compound Annual Growth Rate (CAGR) of approximately -1% to -2%. Growth in emerging markets may offset stagnation in developed countries, driven by increasing hypertension prevalence and healthcare infrastructure improvements.

Long-term (next 5-10 years)

Market consolidation and rising interest in combination therapies may further reduce demand for monotherapy diuretics. The CAGR is projected at around -1%. However, Hydrodiuril will remain a standard, cost-effective diuretic for hypertension, particularly in regions with limited access to newer therapies.

Impact of New Therapeutics

The development of SGLT2 inhibitors, which possess diuretic properties, and novel antihypertensive agents may further suppress demand for Hydrodiuril. Nonetheless, its affordability and extensive safety profile sustain its relevance in low- and middle-income countries.

What factors could influence the future of Hydrodiuril?

• Regulatory Changes: Stricter guidelines favoring combination therapy could reduce monotherapy prescriptions.
• Generic Competition: Intensified price competition may suppress revenues further.
• New Indications: Limited potential for new approved uses. Off-label uses are unlikely.
• Patent Landscape: No relevant patents; no exclusivity extensions expected.

Key Takeaways

• Hydrodiuril's clinical trial activity is minimal; it remains an established, generic antihypertensive.
• The global market is contracting modestly due to competition and evolving treatment paradigms.
• It retains a key role in hypertension management, especially in cost-sensitive settings.
• Market projections indicate a slow negative growth trend over the next decade.
• External factors like regulatory shifts and new therapeutics could accelerate its decline.

FAQs

1. Will Hydrodiuril develop new indications?
No. Current research focuses on its existing indications; no plans for major new approvals.

2. How does Hydrodiuril compare with newer antihypertensives?
It is less effective in resistant hypertension but is more cost-effective and well-tolerated in primary hypertension.

3. Can Hydrodiuril be used with other antihypertensives?
Yes, it is often combined with ACE inhibitors, calcium channel blockers, or ARBs to improve efficacy.

4. What are the main side effects associated with Hydrodiuril?
Electrolyte imbalances (hypokalemia, hyponatremia), dehydration, and increased blood glucose levels.

5. Is Hydrodiuril still relevant in developed markets?
Yes. Its affordability ensures continued use, especially in primary care settings.

References

1. [1] Market data and trends courtesy of IQVIA analysis, 2023.
2. [2] FDA Drug Approvals and Labeling, 1959–2022.
3. [3] American Heart Association Guidelines, 2020.
4. [4] Global hypertension prevalence report, WHO, 2022.
5. [5] Generic drug patent expiry timeline, FDA, 2022.